Trials / Completed
CompletedNCT05315128
Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers
Intralesional Methotrexate Versus Intramuscular Methotrexate in the Treatment of Non-melanoma Skin Cancers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Zagazig University · Other Government
- Sex
- All
- Age
- 20 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
to compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management
Detailed description
Intralesional methotrexate (MTX) could to be promising conservative alternative for non-melanoma skin cancer (NMSC). Systemic MTX was attempted as adjuvant for locally-advanced NMSC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methotrexate | A randomized comparative effectiveness clinical trial |
Timeline
- Start date
- 2020-07-06
- Primary completion
- 2021-08-10
- Completion
- 2021-12-06
- First posted
- 2022-04-07
- Last updated
- 2022-04-07
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05315128. Inclusion in this directory is not an endorsement.